

Punching Above Their Weight Class: High Value-Added Bottlenecks

Artisan Non-U.S. Small-Mid Growth Strategy

PORTFOLIO MANAGER
Viewpoints

September 2021

Our Investment Framework

We seek to be long-term owners in high-quality businesses exposed to structural tailwinds that should drive sustainable growth in end markets. We look for opportunities that emerge at the intersection of growth and change and focus our interest on the subset of well-run, innovative companies with meaningful competitive advantages, structurally high returns on capital, strong balance sheets and the ability to self-finance growth. Wonderful businesses, however, are rarely available at attractive prices, so we look for ways to acquire them in a contrarian fashion in times of adversity or perceived adversity. We aim to double our investors' money over five years and identify smaller companies that can become the industry leaders of tomorrow.

Identifying high value-added "bottlenecks" is a meaningful aspect of our investment approach. The term often conjures up a negative connotation as a critical point of congestion in a manufacturing or flow process that delays throughput. In manufacturing, bottlenecks are the source of many painful inefficiencies. In hospitals, bottlenecks result in longer wait times and potentially worse medical outcomes. Our process looks for companies that *solve* issues related to bottlenecks and provide solutions to customer problems.

Defining High Value-Added Bottlenecks

What makes a bottleneck high value-added? We consider a company to have high value-added bottleneck positioning when its products or services occupy a particularly important position in an industry's value chain but represent only a small portion of the end product's total production cost. Having an outsized value relative to cost is particularly important for many smaller companies that can rarely compete on scale with larger competitors. A company that plays a mission critical role is likely to have the following characteristics: strong market position, brand recognition, product differentiation and high customer intimacy due to factors such as reliability, safety and ease of use. We find such companies also are resilient because they have lower risk of being disintermediated, assuming they continue to innovate.

Over time, smaller companies with these characteristics have demonstrated a greater probability to generate structurally higher returns on capital, higher margins and working capital efficiency as well as command sustained pricing power. Throughout our investment history, we have identified such companies across industries and geographies through our fundamental company research and industry value chain analysis.

For example, let's look at flow control systems for chemical plants or water treatment facilities, which we'll discuss in further detail in the next section. The pipes are the commoditized portion of the industry value chain, having minimal differentiation. On the other hand, pumps, valves and actuators are high value-added bottlenecks that perform mission-critical roles, yet they represent a fraction of the whole system's cost. Another example, which we'll also discuss further in the next section, is food ingredients. Consistent taste, the ability to respond to customer preferences and traceability of ingredients matter—a lot—to consumer product companies. The value a purveyor of ice cream flavors provides far exceeds the price it charges its customers, and furthermore, the cost of flavors is a tiny percentage of the overall cost of the final product.



Rezo Kanovich
Portfolio Manager

24 Years Investment
Experience



Inflation

Inflation has been a topic of intense market scrutiny recently. As we've discussed, our high value-added bottleneck approach results in us selecting companies with two important characteristics—pricing power and high returns on capital. Both are important for inflation protection.

Mission-Critical, Differentiated Sources of Reliability, Safety and Customer Loyalty

The following examples—whether they serve customers that operate in the industrials, pharmaceuticals/biologics or consumer space—provide a mission-critical, differentiated product and/or service that represents a fraction of their customers' total product cost.

Linchpins for Energy Efficiency & Plant Safety

Buildings consume nearly 40% of the world's energy and are a significant source of carbon emissions. The desire to decarbonize and improve buildings' energy efficiency is growing stronger worldwide. Remote monitoring, temperature control and power efficiency measures for new construction as well as the retrofitting of existing buildings will take many years to implement, and these enhancements have only recently begun.



To enable a smart building, you must place sensors and actuators behind the walls. Once installed, these devices remain there for decades, given their initial expense and difficulty to remove. Thus, reliability is paramount. Companies with intellectual property around software-driven, sensor-connected control systems for pumps, valves and actuators allow for predictive maintenance and tend to be bottlenecks, with strong market positions and sustainable pricing power.

One such company is Azbil, which manufacturers automated control systems for HVAC equipment. Azbil has a dominant market share in industrial and commercial buildings in Japan. Its product remains behind a wall for an average of 30 years, making reliability extremely important to its customers. Azbil's return on capital (ROC) of 20% remained steady throughout the pandemic, demonstrating its brand strength, and its multi-year service contracts are sources of durable revenue growth.

Another company providing mission-critical solutions is Rotork, a leader in electric actuators that provides fluid controls for water, chemical, and oil and gas plants. Electric actuators are structurally gaining market share from pneumatic and hydraulic actuators, which have less precise control, require more maintenance and emit hazardous pollutants. The industry's electric mix shift and Rotork's market share gains have historically added

50-100bps to Rotork's annual organic growth rate. An actuator could comprise just 20% of the price of the valve on which it is placed, and valves make up a modest percentage of a process plant's total cost. However, the actuator is critical to controlling process parameters and—when necessary—responding to emergencies. The cost of a \$3,000 actuator failing could cost a process plant tens of millions of dollars in lost revenues. While actuators may seem like fertile ground for competition, there are high barriers to entry due to the intensity of specialization required. Rotork's superior products allow it to price at a premium to competitors and even win projects over competitors who also supply the project's valves. Furthermore, Rotork is improving customer efficiency via digitalization and has a growing, durable revenue stream from service contracts, which currently account for a fifth of total revenue from just 5%-10% of its nearly 4 million installed actuators. We expect Rotork Site Services to expand.

Enablers of Health Care

The revolution in life sciences continues with advancements in molecular diagnostics, pharmaceuticals and new treatment modalities, such as gene and cell therapies. The manufacturing processes for the new treatment modalities are extremely complex and require precision in filtration and purification. For example, the purity requirement for a \$300,000 cancer drug is non-negotiable. In fact, purity standards are so important that companies incorporate them into their FDA filings. Rising complexity, a trend toward outsourcing and the rise of new technologies create opportunities for small companies to succeed.



High value-added bottlenecks exist throughout the healthcare sector, and we have always invested in them with sensitivity to valuation. Investments include MaxCyte, a gene therapy and gene editing company, and Varex Imaging, a leading innovator in X-ray imaging component solutions.

MaxCyte makes equipment for electroporation—a process by which genetic material is inserted into a cell for the mass production of gene-edited drugs. Innovation, world class manufacturing and process excellence have resulted in MaxCyte becoming a licensor to more than 20 gene-editing companies producing next-generation drugs. Vertex Pharmaceuticals' program for cystic fibrosis and sickle cell disease is the most prominent source of royalties. Still in its nascency, MaxCyte has the potential to be a cornerstone company as the wave of gene-editing drugs swells.

Varex Imaging partners with medical, dental and veterinary OEMs as well as with security screening and industrial customers worldwide to bring their products to market faster with innovative technology and high-quality components for X-ray imaging systems. Varex also offers



software solutions and value-added aftermarket services and products, which have long-term, predictable cash flows. The company's end markets are large and growing, and Varex's importance in its respective industry value chains allows it to exercise pricing power and maintain gross profit margins of approximately 35%, even amid a challenging environment.

Purveyors of Ingredients for Flavors, Scents, Nutrition & Personal Care

What is the value of consistent taste and fragrance, safe production processes and traceability of ingredients to consumer products companies? How do these factors shape customer experience, brand reputation and customer loyalty (i.e., willingness to pay)? Ask companies focused on food and nutrition, perfume, cosmetics and personal care, for instance, and you'd hear a common sentiment—value far exceeds cost. Perhaps surprisingly to some, ingredients for flavors, scents and enhanced nutritional properties often influence customer perception more heavily than splashy marketing campaigns. Companies that dependably provide these critical inputs and have the agility to cater to changing customer preferences have an extremely high level of bargaining power, sustainable profitability and high customer lifetime value, despite their small portion of the cost and volume of the end products.



We have been long-term shareholders of Symrise and IMCD, both of which operate in an industry with 3%-4% annual growth globally but have, in our view, higher-than-average growth prospects. Symrise manufactures fragrances, flavorings and cosmetics base materials for over 30,000 household products worldwide, including perfumes, hair and skin care products, toothpaste, food, pet treats and beverages. The company has also added unique value with taste balancing solutions for reduced-sugar concepts and responsibly-sourced, organic options that consumers are increasingly demanding. On average, people interact with products that contain Symrise's ingredients 20-30 times per day. Symrise enjoys gross profit margins of approximately 40%, earnings before interest, taxes, depreciation and amortization (EBITDA) margins of approximately 20%, and operating cash flow that has increased almost every year for the past decade, regardless of economic environment.

Global leader IMCD buys specialty chemicals and ingredients from big suppliers and then mixes or alters them to sell in smaller packages to small customers in industries ranging from food and nutrition to personal care to pharmaceuticals to industrials who cannot buy in bulk. The company also co-creates formulations with its customers that embrace industry trends, requiring precision, an established global supply chain network and production efficiency with digital capabilities. Due to the specialization and typically small percentage of these ingredients relative to a customer's total end product, there is no transparent pricing in the market. Hence, IMCD can fairly easily pass on price inflation to its customers and add a

margin for itself. Alternatively, IMCD does not have to reduce pricing to the same extent when there is price deflation. Highlighting the company's privileged bottleneck positioning, year-over-year gross profit margins grew in 2020 amid a global pandemic, product shortages, and supply chain disturbances and thus far in 2021 amid an economic recovery.

A Side Note on Inflation, Pricing Power and High Returns on Capital

Inflation has been a topic of intense interest over the past few quarters. While in the short term investors may attempt to hedge inflation with speculation on commodities, we believe the best way to combat inflation over the long term is to invest in businesses that command sustainable pricing power and have volume growth, such as companies with high value-added bottleneck positioning.

Persistent inflation could also lead to higher long-term interest rates. We're constantly evaluating the profitability structures of our portfolio companies. The importance of investing in structurally high return on capital businesses is a key point for consideration since the value of a business is driven by the spread between the cost of capital and return on capital. For example, if the cost of capital rises from 2% to 3%, a low return on capital business is massively disadvantaged and would have most of its economic value-add eliminated. In comparison, a high return on capital business would be much less impacted.

A company's capital structure is also important, especially in a rising rate environment. We look for companies that can self-finance growth. As such, our companies typically carry little to no debt, and increases in the cost of capital would have negligible effects on their interest costs or their bottom lines.

Compounding returns in companies with the previously discussed characteristics over a multi-year horizon, in our view, is vastly superior to trying to forecast copper prices. We remain highly price disciplined and continue to focus on structural trends and company fundamentals.

Summary

As always, we are focused on investing for the long term in attractively priced, high-quality businesses that are backed by structural tailwinds. High value-added bottlenecks fit well with our investment approach. By providing their customers outsized value relative to cost, reliability and peace of mind, they are rewarded with resilient business models, sustainable pricing power, structurally high ROC and long-standing customer relationships. High value-added bottlenecks' ability to inextricably link to an industry's value chain and generate strong profitability metrics are what attract us to these long-term investment opportunities.



For more information: Visit www.artisanpartners.com

Current and future portfolio holdings are subject to risk. International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in strategies denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described in Artisan Partners' Form ADV, which is available upon request.

Portfolio Manager: Artisan Non-U.S. Small-Mid Growth Strategy—Rezo Kanovich

This summary represents the views of the portfolio manager as of 30 Sep 2021 and is subject to change without notice. Security examples are for informational purposes only and are not representative of the entire portfolio. There is no guarantee that investment within the securities mentioned will result in profit. While the information contained herein is believed to be reliable, there is no guarantee as to the accuracy or completeness of any statement in the discussion. This material is for informational purposes only and should not be considered as investment advice or a recommendation of any investment service, product or individual security.

Unless otherwise indicated, the Artisan Strategy characteristics relate to that of an investment composite or a representative account managed within a composite. It is intended to provide a general illustration of the investment strategy and considerations used by Artisan Partners in managing that strategy. Individual accounts may differ, at times significantly, from the reference data shown due to varying account restrictions, fees and expenses, and since-inception time periods, among others. Where applicable, this information is supplemental to, and not to be construed with, a current or prospective client's investment account information.

For the purpose of determining the portfolio's holdings, securities of the same issuer are aggregated to determine the weight in the Strategy. The holdings mentioned above comprised the following percentages of a representative account within the Composite's total net assets as of 30 Sep 2023: Azbil Corp 1.8%, Rotork PLC 1.6%, IMCD NV 1.1%, Symrise AG 0.8%. Portfolio holdings are subject to change without notice and are not intended as recommendations of individual securities.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein. We expressly confirm that neither Artisan Partners nor its affiliates have made or are making an investment recommendation, or have provided or are providing investment advice of any kind whatsoever (whether impartial or otherwise), in connection with any decision to hire Artisan Partners as an investment adviser, invest in or remain invested in any funds to which we serve as investment adviser or otherwise engage with Artisan Partners in a business relationship.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is authorized and regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein.

Artisan Partners is not registered, authorized or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorized or lawful. Further limitations on the availability of products or services described herein may be imposed.

In no event shall Artisan Partners have any liability for direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) losses or any other damages resulting from the use of this material.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Professional Clients* or *Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail investors and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. OC351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe, Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292. Registered office: 70 Sir John Rogerson's Quay, Dublin 2, D02 R296 (Company No. 637966).

Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia.

Canada: This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conduct activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws.

© 2023 Artisan Partners. All rights reserved.

For Institutional Investors Only — Not for Onward Distribution

A R T I S A N



P A R T N E R S